Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 77.35M P/E - EPS this Y 6.70% Ern Qtrly Grth -
Income -98.79M Forward P/E -1.00 EPS next Y 22.90% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.62 EPS next 5Y - 52W High Chg -93.00%
Recommedations 2.40 Quick Ratio 7.90 Shares Outstanding 30.17M 52W Low Chg 42.00%
Insider Own 8.04% ROA -51.76% Shares Float 25.71M Beta 0.19
Inst Own 46.37% ROE -87.51% Shares Shorted/Prior 1.71M/1.75M Price 2.57
Gross Margin - Profit Margin - Avg. Volume 187,843 Target Price 10.88
Oper. Margin - Earnings Date May 9 Volume 89,237 Change 0.39%
About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc. News
03/20/24 Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
03/20/24 Q4 2023 Relmada Therapeutics Inc Earnings Call
03/19/24 Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
03/19/24 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
03/12/24 Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
03/05/24 Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
03/04/24 Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
02/01/24 Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares
02/01/24 Relmada Therapeutics CEO & Director Acquires 69% More Stock
01/23/24 Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutions
01/04/24 Relmada Therapeutics Provides Corporate Update
12/29/23 11 Best Psychedelic Stocks to Buy in 2024
11/10/23 Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript
11/08/23 Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results
11/08/23 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/06/23 Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock
11/03/23 Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
10/11/23 Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
10/09/23 Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
10/06/23 Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
RLMD Chatroom

User Image DanPat56 Posted - 3 days ago

$RLMD Victor Mason was right about the (temporary?) fibo bottom.

User Image VictorMason Posted - 4 days ago

$RLMD RLMD shareholders after reading executive compensation: (talk about no skin in the game) https://www.facebook.com/share/r/jGBga8bXPuKPAkkX/?mibextid=xCPwDs

User Image VictorMason Posted - 4 days ago

$RLMD hit the Finonachi support of 3.80, hope it holds

User Image LINGMERTH175 Posted - 5 days ago

$RLMD REL-1017 helps ALS mice. Link is to upcoming Frontiers paper https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1384829/abstract

User Image DanPat56 Posted - 5 days ago

$RLMD Is there a reason for the "almost" nature of this one?

User Image VictorMason Posted - 1 week ago

$RLMD 2 months ago Fibonacci indicated a bottom at 3.80 Wrong Way Steve Cohen of the Mets is back in w 250,000 in December. Rockefeller's VenRock long gone owned 7% at $30. They were So smart none of them wore ties:

User Image ranthor Posted - 1 week ago

$RLMD LMAO, glad I got out last week (didn’t make any money but didn’t lose either). What’s going on now? Did they fail another test or someone else left again?

User Image VictorMason Posted - 1 week ago

$RLMD I voted all my shares as follows: WITHHOLD WITHHOLD FOR AGAINST AGAINST

User Image VictorMason Posted - 1 week ago

$RLMD @$26 they said it would hit $90 ( so did Goldman, Jeffries, Guggenheim...) guess what? It will. The problem making stock predictions is getting the date right. Who knew management could screw up the placebo arms so badly it negated the positive results? I'm going to need a bucket of REL 1017 if they F it up again this fall.

User Image shift_4 Posted - 2 weeks ago

$RLMD next pop could take us up to test $19-20. There's no resistance until there once we get above what we tested on the last run.

User Image Theshermank Posted - 2 weeks ago

@ranthor You can’t even spell properly, and the photo wasn’t irrelevant. It was literally proving my point. Also, I have no connection to the other guy, but to call him psycho, when you act and seem like a paranoid freak is ironic. The fact is that $RLMD could go down to $1 today, and it wouldn’t matter. The only thing that matters is the trial readout in July. Obviously, you don’t have the intelligence to invest in a pharmaceutical company; stick to $NFLX or something.

User Image Theshermank Posted - 2 weeks ago

@ranthor You seem like the psycho one; you’re way too reactionary. $RLMD dipped for a few hours, and you're panicking as if you've never invested in a stock before. Relax Nothing is going to happen until July anyways

User Image ranthor Posted - 2 weeks ago

$RLMD Dead board...like the stock...or the volume...just one psycho who attaches unrelated pics to his posts ..lmao...feels like an asylum here

User Image YouOnlyLiveTwice Posted - 2 weeks ago

$RLMD People still here hoping and praying?

User Image ranthor Posted - 2 weeks ago

$RLMD Down 9% already since my entry...lmao....I should have shorted this again instead of going long...what a joke

User Image VictorMason Posted - 2 weeks ago

$RLMD https://stockcharts.com/h-sc/ui?s=rlmd

User Image VictorMason Posted - 2 weeks ago

$RLMD it ain't over but they need some news about the start of phase 1 on P-11

User Image ranthor Posted - 2 weeks ago

$RLMD Jokes on me LMAO

User Image VictorMason Posted - 2 weeks ago

$RLMD about to go positive on the MACD graph ( bottom black line)

User Image ranthor Posted - 2 weeks ago

$RLMD @VictorMason going long on this one for now...like the chart...make me proud! :D

User Image awisnia13 Posted - 2 weeks ago

@VictorMason Holding an $RLMD bag myself - hopeful it was just bad recruitment!

User Image VictorMason Posted - 2 weeks ago

$RLMD only need 159 days like today to get back to September 2022 level

User Image VictorMason Posted - 2 weeks ago

$HPK $RLMD $CYBN A pshycadelic ETF, twice as much CYBN as RLMD guess they think CYBN is ahead on psylicybin Hoping HPK gets taken over so I can buy more CYBN AND RLMD

User Image Julond Posted - 3 weeks ago

$GME $APM $RLMD

User Image Julond Posted - 3 weeks ago

$APM $ROKU $RLMD $QNT.X

User Image Julond Posted - 3 weeks ago

$APM $ROKU $RLMD

User Image Julond Posted - 3 weeks ago

$APM $RLMD

User Image stoxx0007 Posted - 03/29/24

$SEEL $NRXP $RLMD $HOOD $TSLA

User Image VictorMason Posted - 03/28/24

$RLMD i dont think this will fight the MACD tape until there is news about beginning phase 1 on P-11, just don't know when that might be ( '1st half'? Until they delay it)

User Image Theshermank Posted - 03/27/24

@AnalRetort @VictorMason “This now leaves Praxis with a potential problem. To remain on Nasdaq it must meet the $1 minimum bid price. It’s in danger of not doing that. So, something is to be done. That something is to simply state that 15 old shares are now one new one - a one for 15 reverse stock split: “Praxis Precision Medicines, Inc. (PRAX) will effect a one-for-fifteen (1-15) reverse split“ This doesn’t change the market capitalisation, just the number of shares that make it up. Therefore the stock price reacts mechanically, up 1,500%, or 15x. Which solves that problem of approaching the $1 minimum bid price. It doesn’t, of course, solve the problem of making the drugs work but perhaps that’s something they will now be able to work upon?“ Talk to me when this happens to $RLMD 😂👍

Analyst Ratings
Mizuho Buy Jun 15, 23
SVB Leerink Outperform Jan 23, 23
Goldman Sachs Neutral Oct 14, 22
Guggenheim Neutral Oct 14, 22
Oppenheimer Perform Oct 13, 22
Goldman Sachs Buy Sep 23, 22
Guggenheim Buy Sep 6, 22
Oppenheimer Outperform May 9, 22
Goldman Sachs Buy Mar 24, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TRAVERSA SERGIO Chief Executive Offi.. Chief Executive Officer Jan 29 Buy 3.87 100,000 387,000 244,024 01/31/24
Shenouda Maged Chief Financial Offi.. Chief Financial Officer Jan 29 Buy 3.87 32,675 126,452 34,903 01/31/24
Ence Chuck CA and CO CA and CO Jan 29 Buy 3.86 38,970 150,424 38,970 01/31/24
TRAVERSA SERGIO Chief Executive Offi.. Chief Executive Officer Dec 08 Buy 2.096 55,250 115,804 144,024 12/12/22
Kelly Paul Edward Director Director Apr 04 Option 3.24 10,000 32,400 197,295 04/05/22
Kelly Paul Edward Director Director Apr 04 Sell 30.04 10,000 300,400 187,295 04/05/22
Shenouda Maged CFO CFO Mar 10 Option 3.24 10,000 32,400 12,228 03/10/21
Shenouda Maged CFO CFO Mar 10 Sell 35.39 10,000 353,900 2,228 03/10/21
TRAVERSA SERGIO CEO CEO Feb 16 Option 3.24 1,446 4,685 90,220 02/16/21
TRAVERSA SERGIO CEO CEO Feb 16 Sell 35.43 1,446 51,232 88,774 02/16/21
TRAVERSA SERGIO CEO CEO Feb 10 Option 3.24 11,206 36,307 99,980 02/10/21
TRAVERSA SERGIO CEO CEO Feb 10 Sell 35.17 11,206 394,115 88,774 02/10/21
Kelly Paul Edward Director Director Feb 10 Option 3.24 3,569 11,564 165,864 02/10/21
Kelly Paul Edward Director Director Feb 10 Sell 35.16 3,569 125,486 162,295 02/10/21
Shenouda Maged CFO CFO Feb 10 Sell 35.16 11,372 399,840 2,228 02/10/21
Shenouda Maged CFO CFO Feb 10 Option 3.24 11,372 36,845 13,600 02/10/21
TRAVERSA SERGIO CEO CEO Feb 04 Option 3.24 3,278 10,621 92,052 02/04/21
TRAVERSA SERGIO CEO CEO Feb 04 Sell 35.04 3,278 114,861 88,874 02/04/21
Shenouda Maged CFO CFO Feb 04 Option 3.24 3,200 10,368 5,428 02/04/21
Shenouda Maged CFO CFO Feb 04 Sell 35.02 3,200 112,064 2,228 02/04/21
TRAVERSA SERGIO CEO CEO Jan 29 Option 3.24 10,000 32,400 85,493 01/29/21
TRAVERSA SERGIO CEO CEO Jan 29 Sell 32.69 10,000 326,900 75,493 01/29/21
Kelly Paul Edward Director Director Jan 29 Option 3.24 5,000 16,200 152,295 01/29/21
Kelly Paul Edward Director Director Jan 29 Sell 32.66 5,000 163,300 147,295 01/29/21
Kelly Paul Edward Director Director Jan 26 Option 3.24 4,085 13,235 151,380 01/26/21
Kelly Paul Edward Director Director Jan 26 Sell 912.4 4,085 3,727,154 147,295 01/26/21
TRAVERSA SERGIO CEO CEO Jan 26 Option 3.24 4,070 13,187 79,563 01/26/21
TRAVERSA SERGIO CEO CEO Jan 26 Sell 35.51 4,070 144,526 75,493 01/26/21
Shenouda Maged CFO CFO Jan 26 Option 324 4,000 1,296,000 6,228 01/26/21
Shenouda Maged CFO CFO Jan 26 Sell 35.5 4,000 142,000 2,228 01/26/21
CASAMENTO CHARLES J Director Director Dec 02 Sell 35.74 3,000 107,220 24,950 12/02/20